Navigation Links
HUYA Bioscience Int'l Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
Date:6/17/2008

nic arrhythmia.

Most existing marketed and development-stage anti-arrhythmics have been associated with adverse events such as Torsade de Pointes (TdP - sudden death) or appreciable QTc prolongation (a risk factor for sudden death) in Phase I or preclinical studies. As noted above, in the preclinical studies and the three Phase I studies completed in China, HBI-3000 was well tolerated.

Atrial Fibrillation (AF) is a serious type of arrhythmia found in approximately 2.2 million Americans and about 15 percent of strokes occur in people with AF(1). Ventricular Arrhythmia (VA), a severely abnormal heart rhythm, will cause death unless treated immediately. Ventricular fibrillation (VF), a type of arrhythmia, is responsible for 75 to 85 percent of sudden deaths in persons with heart problems(2).

Currently, anti-arrhythmic drugs are commonly used to treat patients with AF and VA, though in treating patients with VA, most anti-arrhythmics have failed to demonstrate a survival advantage. In some cases they may also carry safety risks, including sudden death. Pre-clinical data developed by HUYA and its Chinese partner, along with the Chinese clinical trial data are encouraging to suggest that HBI-3000 may have a useful role in the treatment of ventricular arrhythmias.

In the United States, HBI-3000 is initially being developed and investigated for use as IV treatment of atrial fibrillation with clinical trials expected to begin in early 2009. "This is a significant area of medicine for which providers need more options to treat patients," continued Gingras. "Researchers in China are developing promising compounds that would fulfill these and other unmet medical needs in the U.S. As we prepare to assemble the data and submit our IND to initiate the Phase I trials, we'll continue to leverage our collaboration and expertise in China and the U.S. It's exciting to think of the amount of time and funding that could be saved by optimizing and streamlining
'/>"/>

SOURCE HUYA Bioscience International
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
2. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
3. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
4. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
5. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
6. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
7. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
10. Neurocrine Biosciences Reports First Quarter 2008 Results
11. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Zimmer Holdings, Inc. (NYSE and SIX: ZMH) is ... patients. Available in both small (6mm) and ... Fixation System from Zimmer is a modular system that offers ... XtraFix System allows surgeons to eliminate steps, as ... resulting in saved time, costs and overall team effort. ...
(Date:3/27/2015)... DALLAS , March 27, 2015 ... Market by Product (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation ... ICE, X-ray)) & Indication (AF, VT, WPW) - Global ... Market is expected to reach around ~$4.73 Billion by ... forecast period 2014 to 2019. Browse ...
(Date:3/27/2015)... 2015  Johnson & Johnson (NYSE: JNJ ) will ... Time) on Thursday, April 23, 2015, from the State Theatre ... Investors and other interested parties may access the live audio ... www.jnj.com and clicking on the webcast icon. ... made available a few hours after the live meeting concludes. ...
Breaking Medicine Technology:Zimmer Debuts New Modular External Fixation System 2Zimmer Debuts New Modular External Fixation System 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4
... in Cellular and Molecular Medicine at Boston Children,s Hospital ... developed a molecular delivery platform that overcomes one of the ... cancer: Making sure the treatment gets to the right place ... PhD, of the PCMM/IDI, and a former fellow from her ...
... 18, 2012  Genetic testing to determine a more accurate initial ... remains rare, but is often done for inappropriate patients, according ... pharmacy benefit manager (PBM). The study will be presented on ... (AMCP),s 24th Annual Meeting & Expo in San Francisco. ...
Cached Medicine Technology:Packaging therapeutic RNAs for targeted treatment of breast cancer 2Packaging therapeutic RNAs for targeted treatment of breast cancer 3Packaging therapeutic RNAs for targeted treatment of breast cancer 4Genetic testing for new warfarin patients is rare, but often inappropriate 2
(Date:3/28/2015)... Coffee could not only perk you up in the morning ... have found. , They found that those who drank coffee ... fight gum disease. Does coffee, then, help fight gum disease? ... Goldman School of Dental Medicine explored in a study ... of Periodontology. , “This is the first long-term study of ...
(Date:3/28/2015)... 2015 "Necrorun" was featured on NewsWatch ... look at the latest and coolest applications on the ... host of NewsWatch and technology expert, conducted the app ... entertaining endless runner game with knights, nature, and peasants. ... in 2009, according to Eurogamer. The popularity of these ...
(Date:3/28/2015)... With more than 4,500 scientists, ... osteoporosis, osteoarthritis and musculoskeletal diseases gathered here for ... the first time in the 17-year history of ... hot-button topic is an emerging non-pharmaceutical protocol for ... principles of Wolff’s law, osteogenic loading at multiples ...
(Date:3/28/2015)... The California-based leading wig brand UniWigs ... shopping on UniWigs during the Easter Holidays from today ... promotion on April Fools’ Day. , As the winter ... the corner. Easter Festival, with religious origins to countries ... holiday after Christmas. The best wig provider, UniWigs, would ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 India ... coverage is made available to all visitors who purchase ... immediately. All members are encouraged to purchase the insurance ... avoid lack of proper coverage for pre-existing medical conditions. ... one or two medical conditions with serious consequences to ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3
... ... Discovery Health, - PREGNANT MAN Premieres Tuesday, November 18, at ... November 19, at 10:00 PM ET/PT -, SILVER SPRING, Md., Nov. ... Thomas Beatie tells the definitive story of,his first pregnancy this Tuesday on ...
... DALLAS, Nov. 13 As Sandy Mullen and ... they were,caring for in the eating disorders unit ... the seemingly successful treatment of a,patient,s primary addiction ... After reviewing hundreds of cases, Mullen, RN, an ...
... 13 Nile Therapeutics,Inc. (Nasdaq: NLTX ), a ... cardiovascular disease, today announced financial results,for the three and ... loss for the three months ended September 30, 2008 ... million, or $0.35 per,share, for the same period of ...
... learned might one day lead to vaccine that works , , ... develop an AIDS vaccine has failed, but researchers report that ... one more effective. , "It,s raised a whole new set ... answer to get us to a successful vaccine," said Dr. ...
... Corp. (Nasdaq:,HMSY) today announced that it will present at ... November 18-19, 2008 at The New,York Palace Hotel., ... at 11:00 am,ET., HMS Holdings Corp. (Nasdaq: ... and program integrity services for government,healthcare programs. The company,s ...
... N.J., Nov. 13 Medco Health,Solutions, Inc. (NYSE: ... Jr., and other members of the Medco senior leadership ... financial results and,business outlook to analysts and investors during ... titled "Inventing World-Class Healthcare,Solutions," is scheduled to begin at ...
Cached Medicine News:Health News:Pregnant Man Thomas Beatie Is Pregnant Again 2Health News:Pregnant Man Thomas Beatie Is Pregnant Again 3Health News:Dallas Addiction Specialists Reveal Discovery in New Book 2Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 2Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 3Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 4Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 5Health News:HIV Vaccine Failure Still Brings Insights 2Health News:Medco to Webcast 2008 Analyst Day Conference 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: